Targeting NR4A1 and NR4A2 to boost glioblastoma treatment response
Official title: “Pharmacologic targeting of NR4A1 and NR4A2 to activate glioblastoma treatment response”
Funded at Methodist Hospital Research Institute · NIH-11389455 · Data updated 2026-11-12
Aimed at making glioblastoma more responsive to standard therapy and immune treatment by blocking NR4A1/NR4A2 with new compounds.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Methodist Hospital Research Institute NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | September 19, 2023 |
| Project end | August 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $552,142 |
| NIH project number | 5R01NS129720-04 |
| Project ID | NIH-11389455 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with glioblastoma or related brain cancers who may be eligible for future translational studies involving NR4A1/NR4A2 inhibitors and combination therapies.
✕Less likely to help
Patients not eligible for future translational studies or those whose tumors do not express NR4A1/NR4A2 targets may not benefit.
What this research studies
Glioblastoma remains deadly despite current treatments. This project tests new dual NR4A1/NR4A2 inhibitors to reprogram the tumor environment and make chemoradiation and immune therapies work better. Researchers will study how these compounds change immune suppression and mesenchymal features in the tumor, and whether they enhance the effects of temozolomide, radiation, and immune checkpoint inhibitors. The work combines laboratory experiments and preclinical testing to support a potential future therapy for GBM patients. If successful, this approach could extend survival and improve quality of life for people with brain cancer.
Why it matters
Potential benefit: If successful, patients with glioblastoma could experience better responses to standard therapy and immune treatments, potentially extending survival.
How similar studies have gone: Preclinical findings in other cancers suggest NR4A1/NR4A2 targeting can boost anti-tumor immunity and treatment responses, with this GBM-directed work building on that foundation.
Where this research is happening
-
Methodist Hospital Research Institute
Houston, United States Active
Researchers
- Principal investigator: Rostomily, Robert C — Methodist Hospital Research Institute
- Study coordinator: Rostomily, Robert C
Related research
Other NIH-funded projects on the same topics.
-
Small molecules to block Slit2/ROBO in glioblastoma
A study to test small molecule drugs that block Slit2/ROBO signals to help treat glioblastoma in patients.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
Small-molecule and biologic treatments for glioblastoma using targeted brain delivery
A new approach aims to use FPS-ZM1 to shrink brain swelling and support immunotherapy for glioblastoma, potentially helping patients recover after surgery.
-
Targeted therapies for glioblastoma in adults and kids
A large NIH program is exploring new brain cancer therapies, including drugs that reach the brain and work against glioblastoma in both children and adults.
-
6-thio-2'-deoxyguanosine for glioblastoma: a new approach to target tumors before surgery
A trial tests a novel drug given before glioblastoma surgery to see how it behaves in the body and within the tumor, and to learn how it affects cancer cells and the immune environment.
-
CD38-Driven Changes in Brain Tumor Metabolism and Immunity in Glioblastoma
A patient-facing look at how scientists plan to study how glioblastoma grows by changing its metabolism and dampening the immune response, with potential targets to help treatment in the future.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.